Intracavitary bleomycin for the control of malignant effusions.
The results of treatment with intracavitary bleomycin are reported in twenty patients with a malignant pleural effusion and five patients with malignant ascites. The control rate was 17/20 (85%) patients with malignant pleural effusions and 3/5 (60%) patients with malignant ascites. Toxicities were minimal with fever being the most common side effect in four patients (16%. Bleomycin is an effective and nontoxic sclerosing agent.
D000328:Adult; D000368:Aged; D001201:Ascites; D001761:Bleomycin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D010996:Pleural Effusion / Q000188:drug therapy; D010997:Pleural Neoplasms / Q000188:drug therapy*
D001761:Bleomycin